A new weight loss injection called CagriSema is producing results that are turning heads in obesity medicine. It combines two powerful ingredients into a single weekly jab — and early trial data suggests it could outperform both Ozempic and Mounjaro. Here is everything UK patients need to know right now.
A new injectable weight loss medicine called CagriSema UK is generating serious attention among doctors and patients alike. Developed by Novo Nordisk — the same company behind Ozempic and Wegovy — it combines two separate drugs into one weekly injection. Early clinical trial results suggest it could help people lose significantly more weight than any currently approved treatment in Britain.
Recent clinical trial results have brought CagriSema into the spotlight among researchers, clinicians and patients interested in the next generation of weight loss treatments.
If you have already heard about Ozempic or Mounjaro and wondered whether something better is on the horizon, CagriSema may be exactly what you are waiting for. But it is not available in the UK yet — and understanding where it stands right now matters before you make any decisions about your own treatment.
What Exactly Is CagriSema?
CagriSema is a combination drug. It pairs semaglutide — the active ingredient in Ozempic and Wegovy — with a newer molecule called cagrilintide. Semaglutide mimics a gut hormone called GLP-1, which reduces appetite and slows digestion. Cagrilintide mimics a different hormone called amylin, which helps regulate how full you feel and how your body processes food.
According to Novo Nordisk, combining these two mechanisms in a single weekly injection produces weight loss results that neither drug achieves alone. The idea is that they work on different parts of your appetite and metabolism at the same time.
According to results from the REDEFINE 1 clinical trial, published in early 2025, people taking the highest dose of CagriSema lost an average of around 22.7 percent of their body weight over 68 weeks. To put that in plain terms: a woman weighing 16 stone could expect to lose roughly 3.5 stone on average. That comfortably beats the roughly 15 percent body weight loss seen with semaglutide alone, according to The New England Journal of Medicine.
It is worth noting the trial did not quite hit its original target of 25 percent weight loss. According to Novo Nordisk, this was partly because a higher than expected number of participants were enrolled at sites where the top dose was not used. Despite this, the results are still considered highly significant by researchers in this field.
What Are the Side Effects?
As with all GLP-1 based medicines, the most commonly reported side effects are nausea, vomiting and diarrhoea, particularly when doses are increased. According to the REDEFINE 1 trial data, these effects were generally mild to moderate and tended to settle over time.
One additional consideration with cagrilintide is injection site reactions — small lumps or redness where the injection is given. According to Novo Nordisk’s published trial data, these occurred more frequently with CagriSema than with semaglutide alone, though they were rarely serious enough to cause people to stop treatment.
No new or unexpected serious safety signals have emerged from the trials so far. However, long-term safety data is still being gathered, as with any medicine still in development.
When Could CagriSema Come to the UK?
CagriSema is not yet approved anywhere in the world. According to Novo Nordisk, the company plans to submit CagriSema for regulatory approval in the United States and Europe in 2025. In the UK, the relevant regulator is the MHRA — the Medicines and Healthcare products Regulatory Agency — which will conduct its own independent review.
Realistically, UK approval is unlikely before 2026 at the earliest. After approval, there would then be a separate process for NICE — the National Institute for Health and Care Excellence — to assess whether the NHS should fund it and for whom. That process typically adds another one to two years.
Private UK clinics could potentially offer CagriSema sooner after MHRA approval, just as they did with Mounjaro before NHS availability. If you are currently exploring private weight loss treatment options, our UK Clinic Reviews section can help you find reputable providers.
If you want to understand how CagriSema fits into the broader landscape of injectable weight loss treatments currently available in Britain, our Weight Loss Jabs Guide covers everything from Ozempic to Mounjaro in plain English.
It is also worth keeping an eye on other emerging treatments. Retatrutide — a triple hormone receptor drug — is also in late-stage trials and could rival CagriSema. You can read our full Retatrutide UK Guide for a detailed comparison.
What This Means For UK Patients
The honest answer is: do not wait for CagriSema before starting treatment if you need help now. The data is genuinely exciting, but approval and NHS availability are still likely years away for most people. If you are struggling with your weight today, Mounjaro is currently the most effective MHRA-approved option available in the UK, with strong clinical evidence behind it. Starting treatment now does not close any doors — you can always transition to newer medicines when they become available under medical supervision. What you should be cautious about is any clinic or website claiming to offer CagriSema in the UK right now. It does not exist in approved form yet. If someone is selling it, that is a significant red flag worth taking seriously.
Frequently Asked Questions
Is CagriSema available in the UK?
No. CagriSema is not currently approved or available in the UK. According to Novo Nordisk, regulatory submissions are planned for 2025, but MHRA review and potential approval is not expected before 2026 at the earliest.
How does CagriSema compare to Mounjaro?
Both are combination drugs targeting multiple hormone pathways. According to the REDEFINE 1 trial, CagriSema produced around 22.7 percent average body weight loss, compared to approximately 20 percent seen with tirzepatide — the active ingredient in Mounjaro — in its own trials. However, direct head-to-head trials have not yet been completed.
Will the NHS fund CagriSema?
It is far too early to say. According to the standard UK process, NICE would need to assess CagriSema’s cost-effectiveness after MHRA approval. Given current NHS pressures and the existing backlog on Wegovy and Mounjaro access, NHS availability could be several years away for most patients.
Are there any UK clinical trials for CagriSema I can join?
Novo Nordisk’s REDEFINE programme has included UK sites in its trials. According to the ClinicalTrials.gov database, further trial phases are ongoing. Your GP can advise whether you might be eligible for any active research programmes.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
Get the UK peptide medicine briefing in your inbox.
Free weekly. No spam. Unsubscribe any time.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment. Information correct at time of publication. The Peptide Brief updates articles when guidance changes.
